A manufacturer of the abortion pill mifepristone, Danco Laboratories, filed an emergency appeal to the US supreme court on Saturday asking it to halt a court decision that would require an in‑person exam before the medication can be prescribed.
The request came hours after the fifth US circuit court of appeals temporarily reinstated the requirement blocking telemedicine health providers from prescribing it to patients by mail in response to a challenge from Louisiana.
